ClinicalTrials.gg
RecruitingNCT07784959Updated Aug 25, 2026

Study of NXP900 With Lorlatinib in ALK+ Lung Cancer

A Phase 1 interventional study of NXP900 and Lorlatinib in ALK Positive, ALK Positive Non-small Cell Lung Cancer and NSCLC, sponsored by Nuvectis Pharma, Inc.. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Nuvectis Pharma, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 521 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Planned enrollment
1,513th of 2,998
54 · median 56
Started
2026
with 130 others
Phase 1
927 of 3,371
134 open now
Primary completion
2027-08
later than 445 of 892 live
Registered
3,344th of 3,371
by date

Among the 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 1,513th largest by planned enrollment of the 2,998 interventional ones that give a count, is one of 131 that started in 2026, is one of 927 in phase 1, reaches primary completion later than 445 of the 892 other live ones, and was the 3,344th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

521 of the 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

516 more — sign in →

All 521 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, open label, Phase 1b study of NXP900 in combination with lorlatinib in subjects with advanced, ALK-positive non-small cell lung cancer (NSCLC)

03

Conditions studied

  • ALK Positive
  • ALK Positive Non-small Cell Lung Cancer
  • NSCLC
  • ALK+ Non-Small-Cell Lung Carcinoma
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years old or older
  • Unresectable, or locally advanced ALK-positive NSCLC.
  • Must have received lorlatinib as first or TKI
  • One prior line of systemic chemotherapy is permitted
  • Must have tolerated the dose level of lorlatinib actively being explored in the study or a higher dose

Exclusion criteria

Exclusion Criteria:

  • Known single or compound ALK domain mutations that cause resistance to lorlatinib, or known actionable oncogenic driver alterations other than ALK with approved targeted therapies available, such as, MET or EGFR mutations or overexpression
  • Any to treatment with lorlatinib according to the lorlatinib United States Prescribing Information (USPI)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Dose Exploration

    Escalating doses of NXP900 given with lorlatinib

    Drug: NXP900 · Drug: Lorlatinib

Interventions

  • DrugNXP900

    NXP900 is an orally administered inhibitor of SRC family kinases (SFK)

  • Lorlatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC)

06

What researchers measure

Primary outcomes

  1. Number of patients with treatment related adverse events and/or clinical laboratory abnormalities

    Time frame: Up to 30 days post treatment

  2. Objective response rate (ORR)

    Best response of complete response (CR) or partial response (PR) per RECIST 1.1

    Time frame: Up to approximately 12 months

  3. Duration of Response (DoR)

    Confirmed CR or PR from the first documented response to the date of documented disease progression or death.

    Time frame: Up to approximately 12 months

  4. Disease Control Rate (DCR)

    The proportion of patients with stable disease (SD), partial response (PR), or complete response (CR).

    Time frame: Up to approximately 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Aug 2027, 12 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 12 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2026
First posted
Aug 25, 2026
StartActual
Aug 17, 2026
Primary completionEst.
Aug 2027
CompletionEst.
Feb 2028
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07784959
Lead sponsor
Nuvectis Pharma, Inc.
Responsible party
Sponsor
First posted
Aug 25, 2026
Start date
Aug 17, 2026
Primary completion
Aug 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Aug 25, 2026

Study contacts

Erin Belshaw
Contact
ebelshaw@nuvectis.com
2016278129
Shay Shemesh
Contact
sshemesh@nuvectis.com
Christine Lovly, MD, PhD
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SRC/YES1 Kinase Inhibitor NXP900

Start the discussion